Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

JERUSALEM, February 14, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.

"We are very pleased to be in close and positive communications with the FDA, as well as having a clear path which meets the FDA's input. This positions us for imminent clearance from the FDA to proceed with our planned clinical studies," commented Nadav Kidron , CEO of Oramed.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... Tengion, Inc. (NASDAQ: TNGN ), a leader ... the Company,s Neo-Urinary Conduit™ (NUC) and Neo-Kidney Augment™ (NUC) ... North America Annual Conference being held December 11-14, in ... further supported by various cellular and molecular studies demonstrating ...
... Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation ... of a Phase 2 study of quizartinib (formerly AC220) ... 53rd Annual Meeting of the American Society of Hematology ... from two additional posters: one evaluating the pharmacodynamic effects ...
... 13, 2011 Tarsa Therapeutics today confirmed that it ... to the Food and Drug Administration (FDA) in the ... recombinant salmon calcitonin tablet for the treatment of postmenopausal ... that verified the results from Tarsa,s Phase III ORACAL ...
Cached Biology Technology:Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 2Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 3Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 2Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 5Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 6Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 7Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 8Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3
(Date:7/14/2014)... East Anglia have shown how the main psychoactive ingredient ... , Research published today reveals the existence of ... drug,s success in shrinking tumours. , It is ... equivalent with anti-cancer properties. , The research ... The team used samples of human breast cancer cells ...
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... Mineral Research awarded Michael F. Holick, PhD, MD, of ... Louis V. Avioli Award. Holick, a professor of medicine, ... revolutionizing the understanding of vitamin D and its role ... member of the American Society for Bone and Mineral ... basic research. It is named for ASBMR,s first president ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... ON Physical activity is being increasingly recognized as ... Mammen,s review published in the October issue of the ... the connection one step further, finding that moderate exercise ... term. This is the first longitudinal review to ...
... Oct. 28, 2013  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2013.  ... decrease of 15% compared to $5.3 million in the same quarter ... was $1.2 million, or $0.05 per diluted share, which compares to ...
... age of agriculture that began in the 1960s, potassium chloride ... widely used as a major fertilizer in the Corn Belt ... recognized for their fundamental importance to soil fertility. Three University ... approach to potassium management that has been in place for ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2013 Financial Results 2Aware, Inc. Reports Third Quarter 2013 Financial Results 3Aware, Inc. Reports Third Quarter 2013 Financial Results 4Aware, Inc. Reports Third Quarter 2013 Financial Results 5Study challenges soil testing for potassium and the fertilizer value of potassium chloride 2Study challenges soil testing for potassium and the fertilizer value of potassium chloride 3Study challenges soil testing for potassium and the fertilizer value of potassium chloride 4
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... Phosphatase ( l-PPase) is ... with activity towards phosphorylated ... residues. It is the ... the ORF221 open reading ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... refrigerated cold traps offers a choice of ... solvents or high volatility solvents. Ideal to ... evaporators. Also used for maintaining vapor-free gas ... in electron microscopes. Can be used as ...
Biology Products: